Alcresta Therapeutics is developing a new class of enzyme-based point-of-care products that can be used in people with compromised pancreatic output and malabsorption to support digestion and absorption of critical nutrients from liquid formula. Alcresta Therapeutics’ point-of-care enzyme based products have the potential to change the management of nutritional care.
Alcresta Therapeutics’ platform technology efficiently and consistently immobilizes (binds) enzymes and attaches them to a wide range of insoluble carriers. The enzymes-carrier complex is used to support the digestion and absorption of critical nutrients in liquid formula. Because of the unique immobilization technology, the enzymes remain active even while adhered to the carrier.
This unique platform technology supports a broad pipeline of products with the potential to improve nutrition and health outcomes.